Previous 10 | Next 10 |
- Quarterly total net product revenue of $19.3 million - - ANNOVERA® TRx of 8,014, an increase of 27% over Q1 2021 - - Announced and completed vitaCare divestiture in five weeks - - Conference call scheduled for 4:30 p.m. ET today - TherapeuticsMD, Inc. (“TXMD&...
-Executive Management to Host Conference Call on May 16, 2022, at 4:30 p.m. ET- TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its first quar...
Biohaven Pharmaceutical BHVN +72% on Q1 results. Evaxion Biotech (EVAX) +54% announces successful production of personalized cancer immunotherapies in phase 1/2a clinical trial for EVX-02. Vroom VRM +36% on Q1 results. Vertex Energy VTNR +16% on Q1 results. ...
Gainers: Better Therapeutics (BTTX) +34%. Great Elm (GEG) +9%. Nuvectis Pharma (NVCT) +8%. Viatris (VTRS) +5%. BioNTech (BNTX) +3%. Losers: TherapeuticsMD (TXMD) -30%. Sutro Biopharma (STRO) -12%. NanoViricides (NNVC) -12%. RedHill Biopharma (RDHL)...
The shares of TherapeuticsMD (NASDAQ:TXMD) have lost ~17% in the pre-market after the women’s healthcare company announced a 1-for-50 reverse stock split on Monday. The Reverse Stock Split took effect on May 06, 2022, at 5:01 p.m. EST following the submission of an amended an...
TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TXMD” or the “Company”) an innovative, leading women’s healthcare company, announced today the closing of the divestiture of vitaCare Prescription Services to GoodRx (NASDAQ: GDRX), in a cash transaction valued at...
Guggenheim has initiated prescription drugs savings platform GoodRx Holdings (NASDAQ:GDRX) with a buy as it offers savings for consumers and higher prescription drug compliance for physicians. The firm has a $24 price target (~28% upside based on Wednesday's close). Analyst Sandy Draper said ...
Want explosive action in the stock market? Start putting together a list of penny stocks. These high-flying names are some of the most captivating, and for a good reason. Few places offer such random liquidity, wild volatility, and extreme breakouts as these cheap stocks. But if you’...
TherapeuticsMD (NASDAQ:TXMD) CFO James C. D’Arecca is resigning from the company effective April 1. Michael C. Donegan, VP, finance and chief accounting officer, will take over as interim CFO. Women's healthcare company TherapeuticsMD (TXMD) also said that it recently received a ...
TherapeuticsMD had a rough 2021, and the share price shows it. The company battled the COVID-19 headwinds and has struggled to expand ANNOVERA’s manufacturing. TherapeuticsMD has an imposing product portfolio. Sadly, the company’s products have struggled to gain traction...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...